SCHEMBL2084580

SCHEMBL2084580

O=C(NC1(CO)CCS(=O)(=O)CC1)c1cnn2c(-c3ccc(C(F)(F)F)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.38

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 2/20 0.38
GPR119 Q8TDV5 11/20 0.37
LCK P06239 2/20 0.35
HCK P08631 2/20 0.35
KDR P35968 2/20 0.35
SRC P12931 1/20 0.35
PDE2A O00408 2/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
NR3C1 P04150 1/20 0.34
HCRTR1 O43613 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2084818 0.90 GPR119 (0.38) GPR119LCKHCKKDRSRC
SCHEMBL2055569 0.90 GPR119 (0.38) DGAT2GPR119LCKHCKKDR
SCHEMBL2084758 0.89 DGAT2 (0.41) DGAT2GPR119PDE2A
SCHEMBL2085221 0.89 GPR119 (0.38) DGAT2GPR119LCKHCKKDR
SCHEMBL2085953 0.89 GPR119 (0.43) DGAT2GPR119PDE2A
SCHEMBL2084319 0.87 MTTP (0.38) GPR119PDE2ANR3C1
SCHEMBL2084591 0.86 DGAT2 (0.46) DGAT2
SCHEMBL2084413 0.83 GPR119 (0.40) DGAT2GPR119LCKHCKKDR
SCHEMBL4115056 0.82 GPR119 (0.41) GPR119LCKHCKKDRSRC
Hydrochloric Acid SCHEMBL2085448 0.82 GPR119 (0.36) GPR119LCKHCKKDRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2035427-B1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORP (JP) 2013-12-11 EP claimed
US-8163759-B2 Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-24 US claimed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US claimed
US-8921380-B2 Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-30 US disclosed
EP-2035427-B1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORP (JP) 2013-12-11 EP disclosed
EP-2520577-A1 Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists Mitsubishi Tanabe Pharma Corporation (JP) 2012-11-07 EP disclosed
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST TANIMOTO KOICHI (JP) 2012-08-09 US disclosed
US-8163759-B2 Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-24 US disclosed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR DGAT2 3629/4885GPR119 224/4885LCK 833/4885
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR DGAT2 3457/4885GPR119 190/4885LCK 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.